NeuroProof
NeuroProof is a Contract Research Organization (CRO) specializing in neuroscience, offering innovative CNS drug discovery technologies, functional phenotypic assays, disease models, and neurotoxicity testing. Their mission is to develop disruptive technologies for CNS drug discovery, providing high predictivity and quality in preclinical services, leveraging microelectrode array (MEA) technology and artificial intelligence for data analysis. They focus on developing new in vitro disease models and screening services to accelerate the development of neuropharmaceuticals and improve safety assessment.
Industries
Nr. of Employees
small (1-50)
NeuroProof
Rostock, Mecklenburg-Vorpommern, Germany, Europe
Products
Standard MEA screening package (NPS Standard Check)
Predefined MEA screening protocol and service package intended for quick ordering and standardized medium-throughput screening of test agents.
Standard MEA screening package (NPS Standard Check)
Predefined MEA screening protocol and service package intended for quick ordering and standardized medium-throughput screening of test agents.
Services
Contract electrophysiology screening of compounds using neuronal cultures on MEA plates, including recording, analysis, and profile comparison against reference data.
In vitro assays for cell viability, cytotoxicity, seizure liability, and prediction of neurological side effects.
Development and execution of disease-relevant neuronal models (epilepsy, ALS, Parkinson's, Alzheimer's, Fragile X, schizophrenia, neuropathic pain) using primary or iPSC-derived neurons.
Advanced spike-train analysis, pattern recognition, and machine-learning workflows to interpret MEA recordings and compare compound profiles.
Automated imaging assays and morphological biomarker quantification to complement electrophysiological endpoints.
Human iPSC line handling, differentiation, and optimization of neuronal stem cell culture protocols for functional assays.
Contract electrophysiology screening of compounds using neuronal cultures on MEA plates, including recording, analysis, and profile comparison against reference data.
In vitro assays for cell viability, cytotoxicity, seizure liability, and prediction of neurological side effects.
Development and execution of disease-relevant neuronal models (epilepsy, ALS, Parkinson's, Alzheimer's, Fragile X, schizophrenia, neuropathic pain) using primary or iPSC-derived neurons.
Advanced spike-train analysis, pattern recognition, and machine-learning workflows to interpret MEA recordings and compare compound profiles.
Automated imaging assays and morphological biomarker quantification to complement electrophysiological endpoints.
Human iPSC line handling, differentiation, and optimization of neuronal stem cell culture protocols for functional assays.
Expertise Areas
- Phenotypic screening using microelectrode arrays
- Neuronal cell culture and iPSC-derived neuronal models
- Electrophysiological data analysis and machine learning
- CNS in vitro disease model development
Key Technologies
- Microelectrode arrays (MEA)
- Primary neuronal co-cultures
- Human iPSC-derived neuronal cultures
- Spike-train analysis
News & Updates
July 03, 2025 – New TDP-43 Mislocalization Assay for ALS in Human iPSC-Derived Motor Neurons: Investigating Wildtype and C9orf72 Model: TDP-43 mislocalization and aggregation are found in 97% of ALS patients, making them key pathological features of the disease. Targeting TDP-43 mislocalization is a promising strategy for ALS therapies.
April 12, 2025 – NeuroProof launches advanced screening assays featuring primary rat neurons.
October 22, 2024 – NeuroProof Systems GmbH and Doppelganger announce a new ALS screening service combining metabolic and electrophysiological analyses for insights into energy metabolism of ALS cells.
July 03, 2025 – New TDP-43 Mislocalization Assay for ALS in Human iPSC-Derived Motor Neurons: Investigating Wildtype and C9orf72 Model: TDP-43 mislocalization and aggregation are found in 97% of ALS patients, making them key pathological features of the disease. Targeting TDP-43 mislocalization is a promising strategy for ALS therapies.
April 12, 2025 – NeuroProof launches advanced screening assays featuring primary rat neurons.
October 22, 2024 – NeuroProof Systems GmbH and Doppelganger announce a new ALS screening service combining metabolic and electrophysiological analyses for insights into energy metabolism of ALS cells.